2025 Targeting immunosuppressive myeloid cells to enhance cancer immunotherapy

Targeting transforming growth factor β to enhance cancer immunotherapy

Human tumours have evolved intricate mechanisms to evade the immune system, either by avoiding recognition or by inhibiting and eliminating immune cells. Although clear evidence exists that the immune system is mobilized in response to tumour growth—a fact that is manifested in the accumulation of numerous immune cells including dendritic cells (DCs), natural killer (NK) cells, macrophages, and...

Chemotherapeutic targeting of cancer-induced immunosuppressive cells.

The expansion of immunosuppressive cells represents a cardinal strategy deployed by tumors to escape from detection and elimination by the immune system. Regulatory T lymphocytes (Treg) and myeloid-derived suppressor cells (MDSC), major components of these inhibitory cellular networks, have drawn intense scrutiny in recent years. In patients with cancer and in animal tumor models, these suppres...

Immunotherapy targeting esophageal cancer stem cells

Esophageal cancer is one of most common malignancies. Cancer stem cells (CSC) are considered to be resistant to chemotherapy and radiotherapy, which might be associated with the recurrence of the tumor after treatment. To find the therapeutic procedures targeting CSCs, the different methods have been used to identify the esophageal CSC-related genes and surface markers. The esophageal CSCs were...

Harnessing the Microbiome to Enhance Cancer Immunotherapy

The microbiota plays a key role in regulating the innate and adaptive immune system. Herein, we review the immunological aspects of the microbiota in tumor immunity in mice and man, with a focus on toll-like receptor (TLR) agonists, vaccines, checkpoint modulators, chemotherapy, and adoptive T cell transfer (ACT) therapies. We propose innovative treatments that may safely harness the microbiota...

Sunitinib-Loaded Polymeric Nanoparticles to Deplete Myeloid-Derived Suppressor Cells and Enhance the Efficacy of a Cancer Immunotherapy